finance
Elutia Reports $3.1 Million in Q1 2026 Net Sales, Up 6% Year-over-Year
Elutia released first-quarter results on May 14, 2026, showing improved gross margin and progress on its automated manufacturing platform. The company anticipates FDA clearance for its NXT41 product in Q4 2026. CEO Randy Mills highlighted the $1.5 billion U.S. breast reconstruction market opportunity during the earnings call.
May 14, 5:55 PM·2m read1 source
BenzingaAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Elutia released financial results for the first quarter ended March 31, 2026 on May 14, 2026 and held its Q1 2026 earnings conference call the same day. 1 million, a 6 percent increase year-over-year. GAAP gross margin reached 58 percent, up from 47 percent in the prior-year period.
The company brought its automated manufacturing platform online during Q1 2026. Randy Mills, Chief Executive Officer of Elutia, said the platform supports a target gross margin in excess of 80 percent at scale. 5 million in cash and escrow.
Elutia is engaged in a process to divest Simpliderm and received inbound acquisition interest in its cardiovascular product line. The company sold its first-generation drug-eluting product Lupro to Boston Scientific for $88 million in October 2025. Lupro was the first FDA-cleared antibiotic-eluting bioenvelope.
Randy Mills laid out the commercial opportunity for the company's next products in breast reconstruction. Approximately 168000 breast reconstruction procedures were performed in the United States in 2025. Biologic mesh is utilized in more than 85 percent of implant-based breast reconstructions.
Biologics account for roughly 65 percent of the total procedural spend in breast reconstruction. Human biologic mesh sells for between $7500 and $9500 per breast. S. 5 billion.
Postoperative infection rates after mastectomy are 15 to 20 percent. One in three women suffer a serious complication after breast reconstruction. Mills said the company is increasingly becoming a pure play drug-eluting biomatrix company focused on one of the largest and most underserved opportunities in reconstructive surgery.
